Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fullerene hydrogel to prevent acute radiation dermatitis
ChiCTR2500102198Phase 2Not yet recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- May 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of fullerene hydrogel in acute radiodermatitis (ARD) (2 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoints: Incidence of acute radiation dermatitis at all grades and Minimum cumulative radiation dose for onset of each grade of acute radiation dermatitis. Planned start May 2025; status: not yet recruiting.
02
Drugs
fullerene hydrogel
03
Conditions
acute radiodermatitis (ARD)
Beyond the preview
Go deeper on ChiCTR2500102198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102198.